Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1. МРНЦ им. А.Ф.Цыба – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 249036, Российская Федерация, г. Обнинск, ул. Королева, д. 4 2. МНИОИ им. П.А.Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 125284, Российская Федерация, г. Москва, 2-й Боткинский проезд, д. 3
Список исп. литературыСкрыть список 1. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–c184. https://doi.org/10.1159/000339789 2. Мирошкина И.В., Грицкевич А.А., Байтман Т.П., Пьяни-кин С.С., Аревин А.Г., Калинин Д.В. и др. Роль маркеров острого повреждения почки в оценке функции почки при ее ишемии. Экспериментальная и клиническая урология. 2018;(4):114–121. 3. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Steh-man-Breen C, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med. 2006 Aug 15;145(4):237–246. https://doi.org/10.7326/0003-4819-145-4-200608150-00003 4. Chmurzynska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 2006;47(1):39–48. https://doi.org/10.1007/BF03194597 5. Munshi R, Johnson A, Siew ED, Ikizler TA, Ware LB, Wurfel MM, et al. MCP-1 gene activation marks acute kidney injury. J Am Soc Nephrol. 2011 Jan;22(1):165–175. https://doi.org/10.1681/ASN.2010060641 6. Andreucci M, Faga T, Pisani A, Perticone M, Michael A. The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice. Eur J Intern Med. 2017 Apr;39:1–8. https://doi.org/10.1016/j.ejim.2016.12.001 7. Mori K, Nakao K. Neutrophil gelatinase-associated lipocalin as the real-time indicator of active kidney damage. Kidney Int. 2007 May;71(10):967–970. https://doi.org/10.1038/sj.ki.5002165 8. Каприн А.Д., Иваненко К.В., Иванов С.А. Контактная уре-теролитотрипсия гольмиевым лазером «MEDILAS H» фирмы «DORNIER». Урология. 2003;(5):43–44. 9. Schmid M, Krishna N, Ravi P, Meyer CP, Becker A, Dalela D, et al. Trends of acute kidney injury after radical or partial nephrec-tomy for renal cell carcinoma. Urol Oncol. 2016 Jul;34(7):293. e1-293.e10. https://doi.org/10.1016/j.urolonc.2016.02.018 10. Cho A, Lee JE, Kwon G-Y, Huh W, Lee HM, Kim Y-G, et al. Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy. Nephrol Dial Transplant. 2011 Nov;26(11):3496–3501. https://doi.org/10.1093/ndt/gfr094 11. Campbell SC, Novick AC, Streem SB, Klein E, Licht M. Compli-cations of nephron sparing surgery for renal tumors. J Urol. 1994 May;151(5):1177–1180. https://doi.org/10.1016/s0022-5347(17)35207-2 12. Patel HD, Pierorazio PM, Johnson MH, Sharma R, Iyoha E, Al-laf ME, et al. Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systemat-ic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1057–1069. https://doi.org/10.2215/CJN.11941116 13. Kjeldsen L, Johnsen AH, Sengeløv H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associ-ated with human neutrophil gelatinase. J Biol Chem. 1993 May 15;268(14):10425–1032. 14. Kjeidsen L, Cowland JB, Borregaard N. Human neutrophilgelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim Biophys Acta. 2000 Oct 18;1482(1–2):272–283. https://doi.org/10.1016/s0167-4838(00)00152-7 15. Abassi Z, Shalabi A, Sohotnik R, Nativ O, Awad H, Bishara B, et al. Urinary NGAL and KIM-1: biomarkers for assessment of acute ischemic kidney injury following nephron sparing surgery. J Urol. 2013 Apr;189(4):1559–1566. https://doi.org/10.1016/j.juro.2012.10.029 16. Koo KC, Hong JH, Lee HS, Jeh SU, Choi YD, Rha KH, et al. Ac-curacy of Urinary Neutrophil Gelatinase-Associated Lipocalin in Quantifying Acute Kidney Injury after Partial Nephrecto-my in Patients with Normal Contralateral Kidney. PLoS One. 2015;10(7):e0133675. https://doi.org/10.1371/journal.pone.0133675 17. Shalabi A, Nativ O, Sumri M, Bishara B, Khoury W, Awad H, et al. Impact of pneumoperitoneum on the post-operative renal function and level of acute kidney injury markers: comparison between laparoscopic and open nephrectomy. Int Arch Urol Complications. 2017;3(2):1–6. https://doi.org/10.23937/2469-5742/1510026 18. Sprenkle PC, Wren J, Maschino AC, Feifer A, Power N, Ghoneim T, et al. Urine neutrophil gelatinase-associated lipo-calin as a marker of acute kidney injury after kidney surgery. J Urol. 2013 Jul;190(1):159–164. https://doi.org/10.1016/j.juro.2013.01.101 19. Lahoud Y, Hussein O, Shalabi A, Nativ O, Awad H, Khamaisi M, et al. Effects of phosphodiesterase-5 inhibitor on ischemic kidney injury during nephron sparing surgery: quantitative assessment by NGAL and KIM-1. World J Urol. 2015 Dec;33(12):2053–2062. https://doi.org/10.1007/s00345-015-1579-3 20. Parekh DJ, Weinberg JM, Ercole B, Torkko KC, Hilton W, Bennett M, et al. Tolerance of the human kidney to isolated con-trolled ischemia. J Am Soc Nephrol. 2013 Feb;24(3):506–517. https://doi.org/10.1681/ASN.2012080786 21. Schmid M, Abd-El-Barr A-E-R, Gandaglia G, Sood A, Olugbade K, Ruhotina N, et al. Predictors of 30-day acute kidney injury fol-lowing radical and partial nephrectomy for renal cell carcinoma. Urol Oncol. 2014 Nov;32(8):1259–1266. https://doi.org/10.1016/j.urolonc.2014.05.002 22. Ichimura TT, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immuno-globulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998 Feb 13;273(7):4135–4142. https://doi.org/10.1074/jbc.273.7.4135 23. Ismail OZ, Zhang X, Bonventre JV, Gunaratnam L. G protein α12 (Gα12) is a negative regulator of kidney injury mol-ecule-1-mediated efferocytosis. Am J Physiol Renal Physiol. 2016 Apr 1;310(7):F607– F620. https://doi.org/10.1152/ajprenal.00169.2015 24. Солохина М.П., Сергеева Н.С., Маршутина Н.В., Ален-тов И.И., Канукоев К.Ю., Нюшко К.М. и др. KIM-1 (kidney injury molecule-1) как потенциальный серологический/урологический опухолеассоциированный маркер почечно-клеточного рака и нефротоксичности химиопрепаратов. Онкоурология. 2019;15(3):132–142. https://doi.org/10.17650/1726-9776-2019-15-3-132-142 25. Yin C, Wang N. Kidney injury molecule-1 in kidney disease. Ren Fail. 2016 Nov;38(10):1567–1573. https://doi.org/10.1080/0886022X.2016.1193816 26. Kaseda R, Iino N, Hosojima M, Takeda T, Hosaka K, Kobayashi A, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun. 2007 Jun 15;357(4):1130–1134. https://doi.org/10.1016/j.bbrc.2007.04.072 27. Uchida K, Gotoh A. Measurement of cystatin-C and creati-nine in urine. Clin Chim Acta. 2002 Sep;323(1–2):121–128. https://doi.org/10.1016/s0009-8981(02)00177-8 28. Chen J, Lin J, Lin C. Serum and urinary biomarkers for pre-dicting acute kidney injury after partial nephrectomy. Clin Invest Med. 2015 May 31;38(3):E82–E89. https://doi.org/10.25011/cim.v38i3.22703 29. Кит О.И., Франциянц Е.М., Димитриади С.Н., Каплиева И.В., Трепитаки Л.К., Черярина Н.Д. и др. Роль маркеров острого повреждения почек в выборе тактики хирургического лече-ния больных раком почки. Онкоурология. 2015;11(3):34–39. https://doi.org/10.17650/1726-9776-2015-11-3-34-39 30. Maatman RG, Van Kuppevelt TH, Veerkamp JH. Two types of fatty acid-binding protein in human kidney. Isolation, char-acterization and localization. Biochem J. 1991 Feb 1;273(Pt 3):759–766. https://doi.org/10.1042/bj2730759 31. Tsigou E, Psallida V, Demponeras C, Boutzouka E, Baltopou-los G. Role of new biomarkers: functional and structural damage. Crit Care Res Pract. 2013;2013:361078. https://doi.org/10.1155/2013/361078 32. Франциянц Е.М., Ушакова Н.Д., Кит О.И., Розенко Д.А., Димитриади С.Н., Шевченко А.Н. и др. Динамика маркеров острого почечного повреждения при резекции почки по поводу рака. Общая реаниматология. 2017;13(6):38–47. https://doi.org/10.15360/1813-9779-2017-6-38-47 33. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, et al. Renal L-type fatty acid--binding protein in acute ischemic injury. J Am Soc Nephrol. 2007 Nov;18(11):2894–902. https://doi.org/10.1681/ASN.2007010097 34. Herget-Rosenthal S, Metzger J, Albalat A, Bitsika V, Mischak H. Proteomic biomarkers for the early detection of acute kidney injury. Prilozi. 2012;33(1):27–48. 35. Slocum JL, Heung M, Pennathur S. Marking renal inju-ry: can we move beyond serum creatinine? Transl Res. 2012 Apr;159(4):277–289. https://doi.org/10.1016/j.trsl.2012.01.014 36. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013 Feb 6;17(1):R25. https://doi.org/10.1186/cc12503 37. FDA News Release: FDA allows marketing of the first test to assess risk of developing acute kidney injury, 2014. Доступно по: https://www.dicardiology.com/content/fda-allows-market-ing-kidney-injury-risk-assessment 38. Sistare FD, Dieterle F, Troth S, Holder DJ, Gerhold D, An-drews-Cleavenger D, et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol. 2010 May;28(5):446–454. https://doi.org/10.1038/nbt.1634 39. Bravi CA, Vertosick E, Benfante N, Tin A, Sjoberg D, Hakimi AA, et al. Impact of Acute Kidney Injury and Its Duration on Long-term Renal Function After Partial Nephrectomy. Eur Urol. 2019 Sep;76(3):398–403. https://doi.org/10.1016/j.eururo.2019.04.040 40. Димитриади С.Н., Ушакова Н.Д., Величко А.В., Франци-янц Е.М., Розенко Д.А. Роль биомаркеров в диагностике реперфузионно-ишемического повреждения почек как показания к проведению лечебного плазмафереза у боль-ных после резекции почки в условиях тепловой ишемии по поводу локализованного почечно-клеточного рака. Совре\менные проблемы науки и образования. 2019;(4):57.